Alamar Biosciences (ALMR) GC John Brottem Receives 29k RSUs & 85k Option Award

What Happened

John L. Brottem, General Counsel of Alamar Biosciences (ALMR), received equity compensation on September 14, 2026 consisting of 29,000 restricted stock units (RSUs) and an 85,000-share derivative award (option). Both awards were granted at $0.00 (no cash paid). The RSUs and options are compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-09-14; Form 4 filed 2026-09-16 (appears timely).
• Grants: 29,000 RSUs (reported as acquisition A) and 85,000 derivative award (reported as acquisition A) at $0.00.
• Vesting (footnotes):
  • RSUs: 25% vest on November 21, 2027; remaining 75% vest in 12 equal quarterly installments thereafter, subject to continued service.
  • Option: 25% vests on September 14, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction were not specified in the provided filing details.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate cashless exercise in the filing.

Context

These are time‑based compensation awards, not sales or purchases on the open market. The option award is a derivative that vests over time and does not represent immediately liquid shares; the RSUs also vest over multiple quarters. Such grants are common for executive compensation and do not, by themselves, signal a buy or sell decision by the insider.